Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29287290 | 0.98 | CHRNA4 (0.33) | CHRNA4MEN1KMT2A | |
| SCHEMBL755172 | 0.81 | CHRNA4 (0.33) | CHRNA4 | |
| SCHEMBL1932936 | 0.68 | — | — | |
| SCHEMBL16599741 | 0.64 | GLRA3 (0.31) | — | |
| SCHEMBL22426580 | 0.64 | — | — | |
| SCHEMBL23989470 | 0.64 | IKBKB (0.41) | KMT2A | |
| SCHEMBL9413725 | 0.64 | KMT2A (0.53) | MEN1KMT2A | |
| SCHEMBL1034980 | 0.64 | LMNA (0.34) | CHRNA4MEN1KMT2A | |
| SCHEMBL7626781 | 0.63 | MKNK1 (0.46) | CHRNA4MEN1KMT2A | |
| SCHEMBL29234047 | 0.63 | HCRTR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108621-A1 | NOVEL USES | NERRE THERAPEUTICS LIMITED (GB) | 2024-04-04 | — | — | US | disclosed |
| US-11872222-B2 | Uses | NERRE THERAPEUTICS LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| EP-4157270-A1 | NEUROKININ (NK)-1 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF PULMONARY FIBROSIS CONDITIONS PROMOTED BY MECHANICAL INJURY TO THE LUNGS | NeRRe Therapeutics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872222-B2 | Uses | TACR1, TACR2, VIPR1 | CHRNA4 479/4885MEN1 1842/4885KMT2A 3533/4885 |
| US-20240108621-A1 | NOVEL USES | TACR1, NTSR1, VIPR1 | CHRNA4 433/4885MEN1 2132/4885KMT2A 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.